Novo Nordisk raises 2026 outlook on Wegovy pill sales

Novo Nordisk lifted its 2026 forecast for a third time after Wegovy pill sales beat expectations.

Objective Facts

Novo Nordisk on Nov. 4, 2026 raised its full-year outlook for the third time this year, now forecasting adjusted sales and operating profit between a 2% decline and 2% growth at constant exchange rates, Reuters reported. The Wegovy pill, launched in the US in January, brought in 5.39 billion Danish crowns in the third quarter, beating the 4.62 billion consensus, with 4.18 billion of that from the US, according to TimesLIVE. Adjusted sales of 79.20 billion crowns and adjusted operating profit of 31.72 billion crowns both topped analyst forecasts, while US sales of the injectable version fell 13%. Novo also raised its free cash flow guidance to 60 to 70 billion crowns and said CFO Karsten Munk Knudsen will leave at the end of December, Tech Times reported. European coverage, including Germany's aktiencheck.de, gave more weight than US outlets to the impairments and the still negative low end of the guidance.

Deep Dive

Novo Nordisk entered 2026 expecting sales and profit to shrink as US prices for its GLP-1 drugs fell and Eli Lilly took share in injectable obesity treatment. The oral version of Wegovy, launched in the US on Jan. 5, has been the main reason the company keeps lifting its forecast. Third quarter pill sales of 5.39 billion crowns rose 53% from the prior quarter, and Zacks Equity Research reported about 3.6 million prescriptions in the quarter and more than 8 million since launch. Tech Times reported that a Medicare pilot charging eligible seniors $50 a month for weight-loss GLP-1 drugs began July 1 and runs through 2027, which widened access to the pill. The bullish case has real numbers behind it: Reuters reported adjusted sales of 79.20 billion crowns against 73.22 billion expected, and Novo estimates it holds about 80% of new-to-brand US prescriptions for obesity pills. The cautious case is also grounded. 24/7 Wall St. reported net price erosion for Wegovy of about 30% in the quarter and a scheduled cut in US list prices for Wegovy and Ozempic to $675 on Jan. 1, 2027. Reported operating profit fell 9% because of impairments tied to ziltivekimab and changes to the production network, according to aktiencheck.de. Doustdar also told Reuters the pill's prescription curve had flattened recently, which he put down to seasonality. Finimize estimated the pill is still only about 6% of expected Wegovy sales, so injectable declines still weigh heavily on the total. Investors will watch whether pill prescriptions resume growth as Lilly's Foundayo gains share of new US prescriptions; Union Investment's Markus Manns told Reuters the market is likely to get tougher. Other dates to track are the accelerated launch in more than 20 countries by mid-2027, the US launch of CagriSema planned for early 2027 subject to approval, and the January handover from Knudsen to new CFO Luigi La Corte, formerly of Galderma.

Regional Perspective

Reuters reporters Jacob Gronholt-Pedersen and Patrick Wingrove, writing from Novo's home market, reported that shares rose as much as 6.6% in early trading before settling about 1.9% higher, and remain more than 70% below their peak. They quoted Copenhagen investor Lars Hytting of ArthaScope: "Novo has the upper hand when it comes to the pill." Germany's aktiencheck.de reported the euro-listed stock up 4.4% to 37.58 euros. Our searches found little Danish-language coverage of the November results themselves. European outlets put more weight on caveats than US market sites did. Aktiencheck.de noted that the guidance range still allows a decline, that adjusted profit growth benefits from a prior-year quarter carrying 9 billion crowns of transformation costs, and that 8.7 billion crowns of impairments cut reported profit. In August, Danish outlet Erhvervsposten's Anders Sørensen wrote that the company's earlier upgrade had not stopped the share price decline, citing Lilly competition and the failed ziltivekimab heart trial. Novo is Denmark's largest company, so the share price affects Danish pension funds and private investors, an audience Erhvervsposten writes for directly. The faster rollout to more than 20 countries by mid-2027 also means European and other non-US patients will gain access to the pill sooner than Novo planned in September.

OBJ SPEAKING

Create StoryTimelinesVoter ToolsRegional AnalysisPolicy GuideAll StoriesCommunity PicksUSWorldPoliticsBusinessHealthEntertainmentTechnologyAbout

Novo Nordisk raises 2026 outlook on Wegovy pill sales

Novo Nordisk lifted its 2026 forecast for a third time after Wegovy pill sales beat expectations.

Nov 4, 2026· Updated Nov 5, 2026
What's Going On
  • On Nov. 4, 2026, Novo Nordisk raised its 2026 outlook for adjusted sales and adjusted operating profit to a range of 2% decline to 2% growth at constant exchange rates, up from a 0% to 6% decline, Reuters reported.
  • Wegovy pill sales reached 5.39 billion Danish crowns (about $810 million) in the third quarter, up 53% from the second quarter and above the 4.62 billion crown consensus, according to Reuters.
  • Adjusted operating profit rose 27% at constant exchange rates to 31.72 billion crowns, while reported operating profit fell 9% after 8.7 billion crowns of noncash impairments, Zacks Equity Research reported.
  • US sales of injectable Wegovy fell 13%, but combined US Wegovy sales rose 21%, and Novo now plans to launch the pill in more than 20 countries by mid-2027, Reuters reported.
  • German outlet aktiencheck.de stressed that the low end of the new range still allows a decline and that the profit jump compares against a weak prior-year quarter.
Region says: European coverage treated the raise as welcome but partial, focusing on Novo's fallen share price, impairments and the still negative low end of guidance.
Objective Deep Dive

Novo Nordisk entered 2026 expecting sales and profit to shrink as US prices for its GLP-1 drugs fell and Eli Lilly took share in injectable obesity treatment. The oral version of Wegovy, launched in the US on Jan. 5, has been the main reason the company keeps lifting its forecast. Third quarter pill sales of 5.39 billion crowns rose 53% from the prior quarter, and Zacks Equity Research reported about 3.6 million prescriptions in the quarter and more than 8 million since launch. Tech Times reported that a Medicare pilot charging eligible seniors $50 a month for weight-loss GLP-1 drugs began July 1 and runs through 2027, which widened access to the pill.

The bullish case has real numbers behind it: Reuters reported adjusted sales of 79.20 billion crowns against 73.22 billion expected, and Novo estimates it holds about 80% of new-to-brand US prescriptions for obesity pills. The cautious case is also grounded. 24/7 Wall St. reported net price erosion for Wegovy of about 30% in the quarter and a scheduled cut in US list prices for Wegovy and Ozempic to $675 on Jan. 1, 2027. Reported operating profit fell 9% because of impairments tied to ziltivekimab and changes to the production network, according to aktiencheck.de. Doustdar also told Reuters the pill's prescription curve had flattened recently, which he put down to seasonality. Finimize estimated the pill is still only about 6% of expected Wegovy sales, so injectable declines still weigh heavily on the total.

Investors will watch whether pill prescriptions resume growth as Lilly's Foundayo gains share of new US prescriptions; Union Investment's Markus Manns told Reuters the market is likely to get tougher. Other dates to track are the accelerated launch in more than 20 countries by mid-2027, the US launch of CagriSema planned for early 2027 subject to approval, and the January handover from Knudsen to new CFO Luigi La Corte, formerly of Galderma.

◈ Tone Comparison

US market coverage leaned upbeat: 24/7 Wall St.'s Chris Lange called the pill's 80% share of new-to-brand prescriptions a "stunning" milestone in his headline. Reuters and Finimize used flatter language, with Finimize warning that investors could sour if pill growth stalls. Germany's aktiencheck.de wrote a hopeful headline but a cautious body, calling the improvement early signals rather than proof of lasting growth.